Design, Synthesis, and Biological Evaluation of Isoform-Selective Akt3 Degraders

Area of Science:

• Molecular Biology
• Medicinal Chemistry
• Oncology

Background:

• The PI3K-Akt-mTOR pathway is crucial in cell signaling and frequently dysregulated in cancer.
• Akt3, a serine/threonine kinase in this pathway, is overactivated in several cancers, presenting a therapeutic target.
• Selective targeting of Akt isoforms is essential to maximize therapeutic benefits and minimize side effects.

Purpose of the Study:

• To design and synthesize novel compounds capable of selectively degrading Akt3.
• To evaluate the impact of linker length and E3 ligand choice on Akt3 degradation.
• To identify a potent and selective Akt3 degrader for potential cancer therapy.

Main Methods:

• Synthesis of a series of compounds varying in linker and E3 ligand.
• Evaluation of compound potency and selectivity for Akt3 degradation in cancer cell lines.
• Proteomic analysis to confirm target specificity and assess off-target effects.

Main Results:

• Linker length and E3 ligand significantly influenced the efficacy of Akt3 degradation.
• Compound 12 demonstrated potent and selective degradation of Akt3 across multiple cancer cell lines.
• Proteomic analysis confirmed Compound 12's specificity for Akt3, with minimal impact on other proteins.

Conclusions:

• Compound 12 is a highly selective Akt3 degrader, validated through chemical synthesis and proteomic studies.
• The findings highlight the potential of targeted protein degradation for cancer therapy.
• Further investigation is needed to explore the therapeutic efficacy of Compound 12, as it lacked antiproliferative activity in vitro.